A detailed history of Atria Investments LLC transactions in Argenx Se stock. As of the latest transaction made, Atria Investments LLC holds 3,060 shares of ARGX stock, worth $1.33 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,060
Previous 3,499 12.55%
Holding current value
$1.33 Million
Previous $1.33 Million 9.54%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 21, 2024

SELL
$356.95 - $413.29 $156,701 - $181,434
-439 Reduced 12.55%
3,060 $1.2 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $123,702 - $184,693
365 Added 11.65%
3,499 $1.33 Million
Q3 2023

Nov 07, 2023

BUY
$369.35 - $548.43 $177,657 - $263,794
481 Added 18.13%
3,134 $1.54 Million
Q2 2023

Aug 04, 2023

BUY
$360.14 - $422.58 $955,451 - $1.12 Million
2,653 New
2,653 $1.03 Million
Q1 2020

May 15, 2020

SELL
$108.83 - $165.23 $74,766 - $113,513
-687 Reduced 14.61%
4,016 $529,000
Q4 2019

Feb 11, 2020

BUY
$106.59 - $164.21 $501,292 - $772,279
4,703 New
4,703 $755,000
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $316,588 - $420,524
-2,794 Closed
0 $0
Q2 2019

Aug 26, 2019

BUY
$115.0 - $141.58 $321,310 - $395,574
2,794 New
2,794 $377,000
Q2 2019

Aug 09, 2019

SELL
$115.0 - $141.58 $315,560 - $388,495
-2,744 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$98.85 - $134.59 $10,873 - $14,804
110 Added 4.18%
2,744 $343,000
Q4 2018

Feb 12, 2019

SELL
$63.81 - $109.82 $14,931 - $25,697
-234 Reduced 8.16%
2,634 $253,000
Q3 2018

Oct 09, 2018

BUY
$75.5 - $96.63 $22,272 - $28,505
295 Added 11.47%
2,868 $218,000
Q2 2018

Jul 13, 2018

BUY
$74.84 - $100.16 $192,563 - $257,711
2,573 New
2,573 $213,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $24.1B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Atria Investments LLC Portfolio

Follow Atria Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atria Investments LLC with notifications on news.